Accelerated DNA methylation age and the use of antihypertensive medication among older adults
The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by...
Gespeichert in:
| Veröffentlicht in: | Aging (Albany, NY.) NY.), 2018-11, Vol.10 (11), p.3210-3228 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3228 |
|---|---|
| container_issue | 11 |
| container_start_page | 3210 |
| container_title | Aging (Albany, NY.) |
| container_volume | 10 |
| creator | Gao, Xu Colicino, Elena Shen, Jincheng Just, Allan C Nwanaji-Enwerem, Jamaji C Wang, Cuicui Coull, Brent Lin, Xihong Vokonas, Pantel Zheng, Yinan Hou, Lifang Schwartz, Joel Baccarelli, Andrea A |
| description | The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (Δ
) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased Δ
between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher Δ
of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality. |
| doi_str_mv | 10.18632/aging.101626 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6286862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2132286057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-c0407aa18165464381eb8bc1d5b649cf979a6ff7b324944de8e473afc28c62ca3</originalsourceid><addsrcrecordid>eNpVkctLxDAQxoMovo9eJUcv1byaphdh8Q2iFz1KSNNpN9Jt1iQV9r83uKvoaWaYH998zIfQCSXnVEnOLkzvxv6cEiqZ3EL7tBZlIUpVb__p99BBjO-EyLIUchftcSKoKGuxj95m1sIAwSRo8fXTDC8gzVeDSc6P2PSAzdjiNAc8RcC-y2Ny89USQoIxuk_IfOvsBl_4scd-aCFg005DikdopzNDhONNPUSvtzcvV_fF4_Pdw9XssbCi5KmwRJDKGKqozP4EVxQa1Vjalo0Ute3qqjay66qGM1EL0YICUXHTWaasZNbwQ3S51l1OTTZkYUzBDHoZ3MKElfbG6f-b0c117z-1ZEoqybLA2UYg-I8JYtILF_NjBjOCn6JmlLOMkrLKaLFGbfAxBuh-z1CivyPR35HodSSZP_3r7Zf-yYB_AeTaihg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2132286057</pqid></control><display><type>article</type><title>Accelerated DNA methylation age and the use of antihypertensive medication among older adults</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Gao, Xu ; Colicino, Elena ; Shen, Jincheng ; Just, Allan C ; Nwanaji-Enwerem, Jamaji C ; Wang, Cuicui ; Coull, Brent ; Lin, Xihong ; Vokonas, Pantel ; Zheng, Yinan ; Hou, Lifang ; Schwartz, Joel ; Baccarelli, Andrea A</creator><creatorcontrib>Gao, Xu ; Colicino, Elena ; Shen, Jincheng ; Just, Allan C ; Nwanaji-Enwerem, Jamaji C ; Wang, Cuicui ; Coull, Brent ; Lin, Xihong ; Vokonas, Pantel ; Zheng, Yinan ; Hou, Lifang ; Schwartz, Joel ; Baccarelli, Andrea A</creatorcontrib><description>The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (Δ
) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased Δ
between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher Δ
of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality.</description><identifier>ISSN: 1945-4589</identifier><identifier>EISSN: 1945-4589</identifier><identifier>DOI: 10.18632/aging.101626</identifier><identifier>PMID: 30414594</identifier><language>eng</language><publisher>United States: Impact Journals</publisher><subject>Aged ; Aging ; Antihypertensive Agents - classification ; Antihypertensive Agents - therapeutic use ; DNA Methylation - physiology ; Humans ; Hypertension - drug therapy ; Research Paper</subject><ispartof>Aging (Albany, NY.), 2018-11, Vol.10 (11), p.3210-3228</ispartof><rights>Copyright © 2018 Gao et al.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-c0407aa18165464381eb8bc1d5b649cf979a6ff7b324944de8e473afc28c62ca3</citedby><cites>FETCH-LOGICAL-c453t-c0407aa18165464381eb8bc1d5b649cf979a6ff7b324944de8e473afc28c62ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286862/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286862/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30414594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Xu</creatorcontrib><creatorcontrib>Colicino, Elena</creatorcontrib><creatorcontrib>Shen, Jincheng</creatorcontrib><creatorcontrib>Just, Allan C</creatorcontrib><creatorcontrib>Nwanaji-Enwerem, Jamaji C</creatorcontrib><creatorcontrib>Wang, Cuicui</creatorcontrib><creatorcontrib>Coull, Brent</creatorcontrib><creatorcontrib>Lin, Xihong</creatorcontrib><creatorcontrib>Vokonas, Pantel</creatorcontrib><creatorcontrib>Zheng, Yinan</creatorcontrib><creatorcontrib>Hou, Lifang</creatorcontrib><creatorcontrib>Schwartz, Joel</creatorcontrib><creatorcontrib>Baccarelli, Andrea A</creatorcontrib><title>Accelerated DNA methylation age and the use of antihypertensive medication among older adults</title><title>Aging (Albany, NY.)</title><addtitle>Aging (Albany NY)</addtitle><description>The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (Δ
) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased Δ
between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher Δ
of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality.</description><subject>Aged</subject><subject>Aging</subject><subject>Antihypertensive Agents - classification</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>DNA Methylation - physiology</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Research Paper</subject><issn>1945-4589</issn><issn>1945-4589</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkctLxDAQxoMovo9eJUcv1byaphdh8Q2iFz1KSNNpN9Jt1iQV9r83uKvoaWaYH998zIfQCSXnVEnOLkzvxv6cEiqZ3EL7tBZlIUpVb__p99BBjO-EyLIUchftcSKoKGuxj95m1sIAwSRo8fXTDC8gzVeDSc6P2PSAzdjiNAc8RcC-y2Ny89USQoIxuk_IfOvsBl_4scd-aCFg005DikdopzNDhONNPUSvtzcvV_fF4_Pdw9XssbCi5KmwRJDKGKqozP4EVxQa1Vjalo0Ute3qqjay66qGM1EL0YICUXHTWaasZNbwQ3S51l1OTTZkYUzBDHoZ3MKElfbG6f-b0c117z-1ZEoqybLA2UYg-I8JYtILF_NjBjOCn6JmlLOMkrLKaLFGbfAxBuh-z1CivyPR35HodSSZP_3r7Zf-yYB_AeTaihg</recordid><startdate>20181110</startdate><enddate>20181110</enddate><creator>Gao, Xu</creator><creator>Colicino, Elena</creator><creator>Shen, Jincheng</creator><creator>Just, Allan C</creator><creator>Nwanaji-Enwerem, Jamaji C</creator><creator>Wang, Cuicui</creator><creator>Coull, Brent</creator><creator>Lin, Xihong</creator><creator>Vokonas, Pantel</creator><creator>Zheng, Yinan</creator><creator>Hou, Lifang</creator><creator>Schwartz, Joel</creator><creator>Baccarelli, Andrea A</creator><general>Impact Journals</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181110</creationdate><title>Accelerated DNA methylation age and the use of antihypertensive medication among older adults</title><author>Gao, Xu ; Colicino, Elena ; Shen, Jincheng ; Just, Allan C ; Nwanaji-Enwerem, Jamaji C ; Wang, Cuicui ; Coull, Brent ; Lin, Xihong ; Vokonas, Pantel ; Zheng, Yinan ; Hou, Lifang ; Schwartz, Joel ; Baccarelli, Andrea A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-c0407aa18165464381eb8bc1d5b649cf979a6ff7b324944de8e473afc28c62ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aging</topic><topic>Antihypertensive Agents - classification</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>DNA Methylation - physiology</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Gao, Xu</creatorcontrib><creatorcontrib>Colicino, Elena</creatorcontrib><creatorcontrib>Shen, Jincheng</creatorcontrib><creatorcontrib>Just, Allan C</creatorcontrib><creatorcontrib>Nwanaji-Enwerem, Jamaji C</creatorcontrib><creatorcontrib>Wang, Cuicui</creatorcontrib><creatorcontrib>Coull, Brent</creatorcontrib><creatorcontrib>Lin, Xihong</creatorcontrib><creatorcontrib>Vokonas, Pantel</creatorcontrib><creatorcontrib>Zheng, Yinan</creatorcontrib><creatorcontrib>Hou, Lifang</creatorcontrib><creatorcontrib>Schwartz, Joel</creatorcontrib><creatorcontrib>Baccarelli, Andrea A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Aging (Albany, NY.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Xu</au><au>Colicino, Elena</au><au>Shen, Jincheng</au><au>Just, Allan C</au><au>Nwanaji-Enwerem, Jamaji C</au><au>Wang, Cuicui</au><au>Coull, Brent</au><au>Lin, Xihong</au><au>Vokonas, Pantel</au><au>Zheng, Yinan</au><au>Hou, Lifang</au><au>Schwartz, Joel</au><au>Baccarelli, Andrea A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Accelerated DNA methylation age and the use of antihypertensive medication among older adults</atitle><jtitle>Aging (Albany, NY.)</jtitle><addtitle>Aging (Albany NY)</addtitle><date>2018-11-10</date><risdate>2018</risdate><volume>10</volume><issue>11</issue><spage>3210</spage><epage>3228</epage><pages>3210-3228</pages><issn>1945-4589</issn><eissn>1945-4589</eissn><abstract>The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (Δ
) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased Δ
between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher Δ
of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality.</abstract><cop>United States</cop><pub>Impact Journals</pub><pmid>30414594</pmid><doi>10.18632/aging.101626</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1945-4589 |
| ispartof | Aging (Albany, NY.), 2018-11, Vol.10 (11), p.3210-3228 |
| issn | 1945-4589 1945-4589 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6286862 |
| source | MEDLINE; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Aged Aging Antihypertensive Agents - classification Antihypertensive Agents - therapeutic use DNA Methylation - physiology Humans Hypertension - drug therapy Research Paper |
| title | Accelerated DNA methylation age and the use of antihypertensive medication among older adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A53%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Accelerated%20DNA%20methylation%20age%20and%20the%20use%20of%20antihypertensive%20medication%20among%20older%20adults&rft.jtitle=Aging%20(Albany,%20NY.)&rft.au=Gao,%20Xu&rft.date=2018-11-10&rft.volume=10&rft.issue=11&rft.spage=3210&rft.epage=3228&rft.pages=3210-3228&rft.issn=1945-4589&rft.eissn=1945-4589&rft_id=info:doi/10.18632/aging.101626&rft_dat=%3Cproquest_pubme%3E2132286057%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2132286057&rft_id=info:pmid/30414594&rfr_iscdi=true |